Google
AVTX 株価分析 — Avalo Therapeutics Inc (Healthcare >> Biotechnology)
AVTX に関するよくある質問
AVTXのROE（自己資本利益率）は？
Avalo Therapeutics IncのROEは-124.03%です。
AVTXの配当利回りは？
Avalo Therapeutics Incの配当利回りは0.00%です。
AVTXの品質スコア（Quality Score）は？
当社のAIはAVTXの総合財務品質を100点中15点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
AVTXは今が買い時ですか？
当社AIのタイミングスコアは100点中89点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
AVTXはどのセクターに属しますか？
Avalo Therapeutics IncはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
AVTX AI Analysis Summary
Our AI summary for AVTX: Avalo Therapeutics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -124.03%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 18.53
Price
0.48
(2.66%)
Day Change
|
|
|---|
AVTX, ファンダメンタルスコアはnot good ( ファンダメンタル = 15) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 18.53 |
| PBV / Sector |
13.98 / 44,022.72
|
| Earning Per Share | -1.64 |
| PE / Sector |
N/A / 19.17
|
| PEG or PE/Growth / Sector |
N/A / 1.24
|
| Average 1M Daily Value |
16.84 M
GREAT
|
| Average 1W Daily Value |
16.09 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-05 07:59:51 |
| Symbol | AVTX |
| Name | AVALO THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 52.90 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 954.90 / 9,586.08 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1500 Liberty Ridge Drive, Wayne, PA, United States, 19087
Phone: 410 522 8707
Website: https://www.avalotx.com
Sector: Healthcare >> Biotechnology
Description: Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
